Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism

Oncotarget

Volumn 5, Issue 19, 2014, Pages 8879-8892

  Yu, Xin ^a,b   Blanden, Adam R ^c   Narayanan, Sumana ^b   Jayakumar, Lalithapriya ^b   Lubin, David ^c   Augeri, David ^d   David Kimball, S ^d   Loh, Stewart N ^c   Carpizo, Darren R ^a,b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Mutant p53 reactivation; Mutant p53 targeted drug; Reactive oxygen species (ROS); Thiosemicarbazone; Zinc metallochaperone

Indexed keywords

ANTINEOPLASTIC AGENT; METALLOCHAPERONE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ZINC; ZINC METALLOCHAPERONE 1; NSC319726; PROTEIN BINDING; PYRIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; MISSENSE MUTATION; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; WILD TYPE; DRUG EFFECTS; GEL MOBILITY SHIFT ASSAY; GENETICS; HCT116 CELL LINE; MCF 7 CELL LINE; METABOLISM; MUTATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HCT116 CELLS; HUMANS; MCF-7 CELLS; METALLOCHAPERONES; MUTATION; PROTEIN BINDING; PROTEIN FOLDING; PYRIDINES; REACTIVE OXYGEN SPECIES; TUMOR SUPPRESSOR PROTEIN P53; ZINC;

EID: 84910072506     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2432     Document Type: Article

References (27)

1. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-339.
2. Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J and Epstein CB. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Ann N Y Acad Sci. 1995; 768:111-128.
3. Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F and Moll UM. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res. 2011; 9(5):577-588.
4. Haupt Y, Maya R, Kazaz A and Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387(6630):296-299.
5. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R and Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007; 445(7128):661-665.
6. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C and Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007; 445(7128):656-660.
7. Martins CP, Brown-Swigart L and Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006; 127(7):1323-1334.
8. Yu X, Vazquez A, Levine AJ and Carpizo DR. Allele-specific p53 mutant reactivation. Cancer Cell. 2012; 21(5):614-625.
9. Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, Lovejoy DB, Sharpe PC, Bernhardt PV and Richardson DR. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem. 2009; 52(17):5271-5294.
10. Cho Y, Gorina S, Jeffrey PD and Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994; 265(5170):346-355.
11. Butler JS and Loh SN. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry. 2003; 42(8):2396-2403.
12. Hainaut P and Milner J. A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Res. 1993; 53(8):1739-1742.
13. Meplan C, Richard MJ and Hainaut P. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene. 2000; 19(46):5227-5236.
14. Loh SN. The missing zinc: p53 misfolding and cancer. Metallomics. 2010; 2(7):442-449.
15. Butler JS and Loh SN. Zn(2+)-dependent misfolding of the p53 DNA binding domain. Biochemistry. 2007; 46(10):2630-2639.
16. Joerger AC and Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene. 2007; 26(15):2226-2242.
17. Colvin RA, Holmes WR, Fontaine CP and Maret W. Cytosolic zinc buffering and muffling: their role in intracellular zinc homeostasis. Metallomics. 2010; 2(5):306-317.
18. Wang Y, Rosengarth A and Luecke H. Structure of the human p53 core domain in the absence of DNA. Acta Crystallogr D Biol Crystallogr. 2007; 63(Pt 3):276-281.
19. Meek DW and Anderson CW. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol. 2009; 1(6):a000950.
20. Hainaut P and Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 1993; 53(19):4469-4473.
21. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS and McMahon SB. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell. 2006; 24(6):841-851.
22. Moran VH, Stammers AL, Medina MW, Patel S, Dykes F, Souverein OW, Dullemeijer C, Perez-Rodrigo C, Serra-Majem L, Nissensohn M and Lowe NM. The relationship between zinc intake and serum/plasma zinc concentration in children: a systematic review and dose-response meta-analysis. Nutrients. 2012; 4(8):841-858.
23. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE and Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med. 2005; 11(12):1306-1313.
24. Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, Givol D and D'Orazi G. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle. 2011; 10(10):1679-1689.
25. Garufi A, Trisciuoglio D, Porru M, Leonetti C, Stoppacciaro A, D'Orazi V, Avantaggiati M, Crispini A, Pucci D and D'Orazi G. A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. J Exp Clin Cancer Res. 2013; 32(1):72.
26. Freed-Pastor WA and Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012; 26(12):1268-1286.
27. Bullock AN, Henckel J and Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene. 2000; 19(10):1245-1256.